Fortrea Holdings Inc. FTRE

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.7% gain over the past six months, beating the S&P 500 by 25.6 percentage points.

Fortrea Holdings has delivered a sharp share price move over the past year, which puts the focus squarely on whether that jump lines up with the cash the business can generate. With the stock now reflecting both recent momentum and fresh deal activity, investors are asking if today’s valuation is grounded in the company’s underlying cash flows or leaning more on optimism. Fortrea Holdings has returned about 129.1% over the past year, which puts meaningful pressure on the cash flow outlook to...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

While M&A expands one-stop shop capabilities at large CROs, pharma companies could face tradeoffs around niche expertise and service continuity.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees. Included in these awards were grants of employment inducement awards to Jason Knoblauch, the Company’s recently appointed Chief Financial Officer, as an inducement material to

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September: Baird 2026 Global Healthcare Conference (NYC) Date: Tuesday, September 15, 2026Format: Fireside Chat & 1x1 and Group MeetingsTime: 2:00 -2:30 PM EDTWebcast: FTRE Baird Webcast Deutsche Bank 2026 Healthcar

Check out the companies making headlines this week:

Check out the companies making headlines yesterday:

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 3% in the afternoon session after the company agreed to acquire the Early Phase Services division of Worldwide Clinical Trials.

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea’s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth marketsHighlights Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical TrialsIncludes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen stora

Fortrea has been on fire lately. In the past six months alone, the company’s stock price has rocketed 77%, reaching $18.31 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Fortrea (NASDAQ:FTRE) and the best and worst performers in the drug development inputs & services industry.

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.

Investment management company Curreen Capital released its second-quarter 2026 Investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 22.26% compared to 15.20% for the S&P 500 Index. The performance was driven by active special case investments, including buying a tender offer, a merger-spinoff, and investments in […]

Fortrea Holdings (FTRE) is back in focus after reporting Q2 2026 results that exceeded analyst expectations and lifting its full year 2026 revenue and EBITDA guidance, citing stronger biotech demand and tighter execution. See our latest analysis for Fortrea Holdings. At a share price of $18.43, Fortrea Holdings has a 90 day share price return of 22.95% and a 1 year total shareholder return of 180.09%. This suggests momentum has picked up recently despite earlier three year total shareholder...

In late July 2026, Fortrea Holdings Inc. raised its full-year 2026 revenue guidance to US$2.62 billion–US$2.69 billion and reported second-quarter sales of US$678.2 million alongside a sharply reduced net loss of US$13.2 million versus a year earlier. On the governance side, the board appointed director David Smith as Interim Chief Financial Officer after a court order placed recently hired CFO Jason Knoblauch on paid leave, adding an experienced pharmaceutical finance leader to oversee...